Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

INTRODUCTION: Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse ev...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Semin Arthritis Rheum
Auteurs principaux: Cappelli, Laura C., Brahmer, Julie R., Forde, Patrick M., Le, Dung T., Lipson, Evan J., Naidoo, Jarushka, Zheng, Lei, Bingham, Clifton O., Shah, Ami A.
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6150859/
https://ncbi.nlm.nih.gov/pubmed/29573850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.semarthrit.2018.02.011
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires